HK1029941A1 - Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative - Google Patents

Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative

Info

Publication number
HK1029941A1
HK1029941A1 HK01100914A HK01100914A HK1029941A1 HK 1029941 A1 HK1029941 A1 HK 1029941A1 HK 01100914 A HK01100914 A HK 01100914A HK 01100914 A HK01100914 A HK 01100914A HK 1029941 A1 HK1029941 A1 HK 1029941A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
side effects
acid derivative
reduced side
hydroximic acid
Prior art date
Application number
HK01100914A
Other languages
English (en)
Inventor
Balazs Sumegi
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Publication of HK1029941A1 publication Critical patent/HK1029941A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK01100914A 1997-06-23 2001-02-09 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative HK1029941A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701081A HU9701081D0 (en) 1997-06-23 1997-06-23 Pharmaceutical composition of antitumoral activity
PCT/IB1998/000961 WO1998058676A1 (fr) 1997-06-23 1998-06-22 Composition pharmaceutique presentant une activite antitumorale amelioree et/ou des effets secondaires reduits contenant un agent antitumoral et un derive d'acide hydroximique

Publications (1)

Publication Number Publication Date
HK1029941A1 true HK1029941A1 (en) 2001-04-20

Family

ID=89995266

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01100914A HK1029941A1 (en) 1997-06-23 2001-02-09 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative

Country Status (25)

Country Link
US (4) US6440998B1 (fr)
EP (1) EP0993304B1 (fr)
JP (1) JP2002508762A (fr)
KR (1) KR20010020496A (fr)
CN (1) CN1127984C (fr)
AT (1) ATE235918T1 (fr)
AU (1) AU735922B2 (fr)
BR (1) BR9810312A (fr)
CA (1) CA2294913C (fr)
CZ (1) CZ298468B6 (fr)
DE (1) DE69812949T2 (fr)
DK (1) DK0993304T3 (fr)
ES (1) ES2195344T3 (fr)
HK (1) HK1029941A1 (fr)
HU (1) HU9701081D0 (fr)
IL (1) IL133508A (fr)
NO (1) NO322206B1 (fr)
NZ (1) NZ502039A (fr)
PL (1) PL191718B1 (fr)
PT (1) PT993304E (fr)
RU (2) RU2214238C2 (fr)
SK (1) SK282877B6 (fr)
TR (1) TR199903214T2 (fr)
UA (1) UA64757C2 (fr)
WO (1) WO1998058676A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884424B2 (en) * 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP2368554B1 (fr) 2003-04-08 2014-12-24 Progenics Pharmaceuticals, Inc. Formulations pharmaceutiques contenant de la methylnaltrexone
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662390B2 (en) * 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
PE20130480A1 (es) * 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
EP3263571B2 (fr) * 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Forme cristalline de bromure de (r)-n-methylnaltrexone et utilisations associées
MX2009010515A (es) * 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
NZ584849A (en) * 2007-10-30 2012-04-27 Trophos Novel composition for treating the side effects of anticancer treatments
WO2009074835A1 (fr) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Réduction de dose d'un antagoniste des récepteurs cannabinoïdes cb1 dans le traitement d'un surpoids ou de l'obésité
CA2713568C (fr) * 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation et utilisation de (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (fr) 2008-03-21 2019-10-09 The University of Chicago Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) * 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
US9938279B2 (en) * 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
CN108703970A (zh) * 2013-09-18 2018-10-26 华安医学股份有限公司 一种活化ampk的化合物及其用途
RU2679136C1 (ru) * 2018-03-13 2019-02-06 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН, КНЦ СО РАН) Способ получения препарата на основе взаимодействия цис-диамин(циклобутан-1,1-дикарбоксилат-о,о')платины(ii) с арабиногалактаном
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
CZ286412B6 (en) * 1993-03-31 2000-04-12 Merck & Co Inc Synergetic combination of compounds for treating AIDS, pharmaceutical preparation containing such synergetic combination and use of this synergetic combination for preparing pharmaceutical preparation
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
DK0993304T3 (da) 2003-07-28
IL133508A0 (en) 2001-04-30
CZ462599A3 (cs) 2000-05-17
RU2254129C2 (ru) 2005-06-20
US20020147213A1 (en) 2002-10-10
CA2294913C (fr) 2008-12-16
WO1998058676A1 (fr) 1998-12-30
BR9810312A (pt) 2000-09-19
CA2294913A1 (fr) 1998-12-30
UA64757C2 (uk) 2004-03-15
TR199903214T2 (xx) 2000-12-21
NO322206B1 (no) 2006-08-28
NZ502039A (en) 2002-03-28
CN1127984C (zh) 2003-11-19
EP0993304A1 (fr) 2000-04-19
SK176499A3 (en) 2000-09-12
JP2002508762A (ja) 2002-03-19
ES2195344T3 (es) 2003-12-01
CN1263471A (zh) 2000-08-16
AU7783798A (en) 1999-01-04
US6720337B2 (en) 2004-04-13
NO996349L (no) 2000-02-23
KR20010020496A (ko) 2001-03-15
DE69812949D1 (de) 2003-05-08
PT993304E (pt) 2003-08-29
SK282877B6 (sk) 2003-01-09
PL191718B1 (pl) 2006-06-30
PL337719A1 (en) 2000-08-28
AU735922B2 (en) 2001-07-19
US6440998B1 (en) 2002-08-27
US6838469B2 (en) 2005-01-04
ATE235918T1 (de) 2003-04-15
NO996349D0 (no) 1999-12-20
CZ298468B6 (cs) 2007-10-10
HU9701081D0 (en) 1997-08-28
US20030069270A1 (en) 2003-04-10
EP0993304B1 (fr) 2003-04-02
RU2214238C2 (ru) 2003-10-20
DE69812949T2 (de) 2004-02-05
IL133508A (en) 2005-11-20
US20030050345A1 (en) 2003-03-13
US6656955B2 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
HK1029941A1 (en) Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative
CA2171275A1 (fr) Derives du stilbene et compositions pharmaceutiques qui en renferment
EP1731140A3 (fr) Formulation d'aerosol medicinal
CA2295035A1 (fr) Formulations pharmaceutiques contenant du voriconazole
CA2416403A1 (fr) Formulation medicinale d'aerosol
CA2304704A1 (fr) Formulations et procedes de reduction de la toxicite d'agents antineoplasiques
EP1135173A4 (fr) Formulation d'aerosol medicamenteuse
GEP20033025B (en) 4,4-Biarylpiperidine Derivatives with Opioid Receptor Activity
CA2180571A1 (fr) Agents de chimioprevention ou de chimiotherapie du cancer du colon a base de derives de l'acide 2-hydroxy-5-phenylazobenzoique
WO2000045800A3 (fr) Effets immunosuppresseurs des derives de pteridine
HUP0002037A3 (en) Hydroximic acid derivatives, use of them for producing pharmaceutical compositions suitable for inhibiting matrix metalloproteinas and pharmaceutical compositions containing the compounds
CA2233315A1 (fr) Compositions pharmaceutiques contenant des derives d'acide hydroximique
HUP0202788A3 (en) Indolyl-3-glyoxylic acid derivatives serving as antitumor agents and pharmaceutical compositions containing them
HUP0002853A3 (en) 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, and pharmaceutical compositions containing them
HUP9700005A3 (en) 2-ureido-benzamide derivatives and pharmaceutical compositions containing them as active agent
YU8701A (sh) Nova oralna kompozicija
AU6309698A (en) Drugs containing aminopyridine derivatives as the active ingredient
TW200420557A (en) Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
ZA966576B (en) Hydroximic acid derivatives, processes for their preparation, and compositions comprising them.
CA2347750A1 (fr) Composition pharmaceutique contenant de la decursine
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
HK1041000A1 (en) Novel pyrimidine derivatives and processes for thepreparation thereof.
CA2182812A1 (fr) Composition pharmaceutique pour administration transdermique systemique contenant du morphine-6-glucoronide comme principe actif

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090622